Sustained citalopram treatment in experimental hepatic encephalopathy: Effects on entrainment to the light-dark cycle and melatonin

Basic and Clinical Pharmacology and Toxicology

Volumn 99, Issue 1, 2006, Pages 80-88

  Kugelberg, Fredrik C ^a   Apelqvist, Gustav ^b   Carlsson, Björn ^a   Ahlner, Johan ^a,c   Bengtsson, Finn ^a,b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c DEPARTMENT OF FORENSIC GENETICS AND FORENSIC TOXICOLOGY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; DEMETHYLCITALOPRAM; DIDEMETHYLCITALOPRAM; DRUG METABOLITE; MELATONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CIRCADIAN RHYTHM; CONTROLLED STUDY; ENANTIOMER; HEPATIC ENCEPHALOPATHY; HORMONE ACTION; LIGHT DARK CYCLE; LOCOMOTION; MALE; NIGHT; NONHUMAN; OPEN FIELD BEHAVIOR; PORTOCAVAL SHUNT; PRIORITY JOURNAL; RAT; REARING;

ANIMALS; ANTIDEPRESSIVE AGENTS; CIRCADIAN RHYTHM; CITALOPRAM; DARKNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG IMPLANTS; HEPATIC ENCEPHALOPATHY; LIGHT; MALE; MELATONIN; MOTOR ACTIVITY; PORTACAVAL SHUNT, SURGICAL; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM;

EID: 33745815170     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2006.pto_449.x     Document Type: Article

References (60)

1. Apelqvist, G., B. Hindfelt, G. Andersson & F. Bengtsson: Central vs. peripheral spontaneous behavioral abnormalities in experimental hepatic encephalopathy. Physiol. Behav. 1997, 61, 851-856.
2. Apelqvist, G., B. Hindfelt, G. Andersson & F. Bengtsson: Diurnal and gender effects by chronic portacaval shunting in rats on spontaneous locomotor and rearing activities in an open-field. Behav. Brain Res. 1998, 93, 25-32.
3. Apelqvist, G., C. Wikell, B. Carlsson, S. Hjorth, P. B. F. Bergqvist, J. Ahlner & F. Bengtsson: Dynamic and kinetic effects of chronic citalopram treatment in experimental chronic hepatic encephalopathy. Clin. Neuropharmacol. 2000, 23, 304-317.
4. Beaubernard, C., F. Salomon, D. Grange, M. J. Thangapregassam & J. Bismuth: Experimental hepatic encephalopathy. Changes of the level of wakefulness in the rat with portacaval shunt. Biomedicine 1977, 27, 169-171.
5. Bengtsson, F., F. H. Gage, B. Jeppsson, A. Nobin & E. Rosengren: Brain monoamine metabolism and behavior in portacaval-shunted rats. Exp. Neurol. 1985, 90, 21-35.
6. Bengtsson, F., M. Bugge, A. Brun, B. Falck, K. G. Henriksson & A. Nobin: The impact of time after portacaval shunt in the rat on behavior, brain serotonin, and brain and muscle histology. J. Neurol. Sci. 1988, 83, 109-122.
7. Bengtsson, F.: Neurotransmission failure in hepatic encephalopathy involving the combined action of different brain tryptophan-related pathology: A speculative synthesis. In: Advances in tryptophan research. Eds.: I. Isbiguro, R. Kido, T. Nagatsu, Y. Nagamura & Y. Obta. Fujita Health University Press, Toyoake, Japan, 1992, pp. 303-308.
8. Bengtsson, F. & P. Bergqvist: Neuropsychiatric implications of brain tryptophan perturbations appearing in hepatic encephalopathy. Adv. Exp. Med. Biol. 1996. 398, 387-395.
9. Bengtsson, F., P. B. F. Bergqvist & G. Apelqvist: Brain tryptophan perturbations in hepatic encephalopathy: implications for effects by neuropsychiatric drugs in clinical practice. Adv. Exp. Med. Biol. 1997, 420, 1-33.
10. Bengtsson, F.: Brain tryptophan/serotonin perturbations in metabolic encephalopathy and the hazards involved in the use of psychoactive drugs. Adv. Exp. Med. Biol. 1999, 467, 139-54.
11. Bergeron, M., M. S. Swain, T. A. Reader, L. Grondin & R. F. Butterworth: Effect of ammonia on brain serotonin metabolism in relation to function in the portacaval shunted rat. J. Neurochem. 1990, 55, 222-229.
12. Bergqvist, P. B. F., B. A. P. M. Vogels, D. K. Bosman, M. A. W. Maas, S. Hjorth, R. A. F. M. Chamuleau & F. Bengtsson: Neocortical dialysate monoamines of rats after acute, subacute, and chronic liver shunt. J. Neurochem. 1995, 64, 1238-1244.
13. Bergqvist, P. B. F., S. Hjorth, G. Apelqvist & F. Bengtsson: Potassium-evoked neuronal release of serotonin in experimental chronic portal-systemic encephalopathy. Metab. Brain Dis. 1997a, 12, 193-202.
14. Bergqvist, P. B. F., C. Wikell, S. Hjorth, G. Apelqvist & F. Bengtsson: Effect of citalopram on brain serotonin release in experimental hepatic encephalopathy: implications for thymoleptic drug safety in liver insufficiency. Clin. Neuropharmacol. 1997b, 20, 511-522.
15. Borg, J., J. M. Warter, J. L. Schlienger, M. Imler, C. Marescaux & G. Mack: Neurotransmitter modifications in human cerebro-spinal fluid and serum during hepatic encephalopathy. J Neurol. Sci. 1982, 57, 343-356.
16. Brzezinski, A.: Melatonin in humans. New Engl. J. Med. 1997, 336, 186-195.
17. Carlsson, B. G. Olsson, M. Reis, J. Wålinder, C. Nordin, J. Lundmark, M. G. Scordo, M. L. Dahl, F. Bengtsson & J. Ahlner: Enantioselective analysis of citalopram and metabolites in adolescents. Ther. Drug Monit. 2001, 23, 658-664.
18. Conjeevaram, H. S., K. D. Mullen, E. J. May & A. J. McCullough: Gender-dependent reduction of spontaneous motor activity and growth in rats subjected to portacaval shunt. Hepatology 1994a, 19, 381-388.
19. Conjeevaram, H. S., A. Nagle, A. Katz, K. Kaminsky-Russ, A. J. McCullough & K. D. Mullen: Reversal of behavioral changes in rats subjected to portacaval shunt with oral neomycin therapy. Hepatology 1994b, 19, 1245-1250.
20. Conn, H. O. & M. M. Lieberthal: The hepatic coma syndromes and lactulose. Williams & Wilkins, Baltimore, 1979.
21. Cordoba, J., J. Cabrera, L. Lataif, P. Penev, P. Zee & A. T. Blei: High prevalence of sleep disturbance in cirrhosis. Hepatology 1998, 27, 339-345.
22. DeVane, C. L.: Pharmacokinetics of newer antidepressants: clinical relevance. Amer. J. Med. 1994, 97, 13S-23S.
23. Frazer, A. & J. G. Hensler: Serotonin. In: Basic neurochemistry. Eds.: G. J. Siegel, B. W. Agranoff, R. W. Albers & P. B. Molinoff. Raven Press, Ltd., New York, NY, U.S.A., 1994, pp. 283-308.
24. Gorka, Z. & J. Maj: Effects of repeated treatment with antidepressant drugs on the 24 hour behavior in the light-dark synchronized mice. Pol. J. Pharmacol. Pharm. 1986, 38, 493-499.
25. Groeneweg, M., J. C. Quero, I. De Bruijn, I. J. Hartmann, M. L. Essink-bot, W. C. Hop & S. W. Schalm: Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 1998, 28, 45-49.
26. Hale, A. S.: New antidepressants: use in high-risk patients. J. Clin. Psychiatry 1993, 54, 61-70.
27. Hjorth, S. & S. B. Auerbach: Further evidence for the importance of 5-HT1A autoreceptors in the action of selective serotonin reuptake inhibitors. Eur. J. Pharmacol. 1994, 260, 251-255.
28. Hjorth, S., H. J. Bengtsson & S. Milano: Raphe 5-HT1A autoreceptors, but not postsynaptic 5-HT1A receptors or beta-adrenoceptors, restrain the citalopram-induced increase in extracellular 5-hydroxytryptamine in vivo. Eur. J. Pharmacol. 1996, 316, 43-47.
29. Holm, E., W. Uhl & S. Stamm: Safety of fluvoxamine for patients with chronic liver disease: biochemical variables, psychometric performance and EEG. Adv. Pharmacother. 1986, 2, 151-165.
30. Hohn, E., S. Jacob, C. Kortsik, H. Leweling & B. Fischer: Failure of selective serotonin reuptake inhibition to worsen the mental state of patients with subclinical hepatic encephalopathy. In: Advances in ammonia metabolism and hepatic encephalopathy. Eds.: P. B. Soeters, J. H. P. Wilson, A. J. Meijer & E. Holm. Elsevier Science Publishers B.V., Amsterdam, Netherlands, 1988, pp. 474-486.
31. Hyttel, J.: Effect of a selective 5-HT uptake inhibitor - Lu 10-171-on rat brain 5-HT turnover. Acta pharmacol. et toxicol. 1977, 40, 439-446.
32. Hyttel, J., K. P. Bøgesø, J. Perregaard & C. Sánchez: The pharmacological effect of citalopram resides in the (S)-(+)- enantiomer. J. Neural Transm. Gen. Sect. 1992, 88, 157-160.
33. Härtter, S. X. Wang, H. Weigmann, T. Friedberg, M. Arand, F. Oesch & C. Hiemke: Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J. Clin. Psychopharmacol. 2001, 21, 167-174.
34. Krastev, Z., D. Terziivanov, V. Vlahov, A. Maleev, W. H. Greb, K. M. Eckl, H. D. Dierdorf & D. Wolf: The pharmacokinetics of paroxetine in patients with liver cirrhosis. Acta Psychiatr. Scand. Suppl. 1989, 350, 91-92.
35. Kugelberg, F. C., G. Apelqvist, B. Carlsson, J. Ahlner & F. Bengtsson: In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats. Brit. J. Pharmacol. 2001, 132, 1683-1690.
36. Kugelberg, F. C., G. Apelqvist & F. Bengtsson: Effects of chronic citalopram treatment on central and peripheral spontaneous open-field behaviours in rats. Pharmacology & Toxicology 2002, 90, 303-310.
37. Lee, S. H. & B. Fisher: Portocaval shunt in the rat. Surgery. 1961, 50, 668-672.
38. Martin, J. R.: Discordant motor activity levels of portacaval-shunted rats in runway and swim tests. Behav. Neurosci. 1986, 100, 427-437.
39. Moore-Ede, M. C., C. A. Czeisler & G. S. Richardson: Circadian timekeeping in health and disease. Part 2. Clinical implications for circadian rhythmicity. New Engl. J. Med. 1983, 309, 530-536.
40. Mousseau, D. D. & R. F. Butterworth: Current theories on the pathogenesis of hepatic encephalopathy. Proc. Soc. Exp. Biol. Med. 1994, 206, 329-344.
41. Rehnström, S., G. Simert, J. A. Hansson, G. Johnson & J. Vang: Chronic hepatic encephalopathy. A psychometrical study. Scand. J. Gastroenterol. 1977, 12, 305-311.
42. Reppert, S. M. & D. R. Weaver: Melatonin madness. Cell 1995, 83, 1059-1062.
43. Rikkers, L., P. Jenko, D. Rudman & D. Freides: Subclinical hepatic encephalopathy: detection, prevalence and relationship to nitrogen metabolism. Gastroenterology 1978, 75, 462-469.
44. Rössle, M., M. Luft, R. Herz, B. Klein, M. Lehmann, & W. Gerok. Amino acid, ammonia and neurotransmitter concentrations in hepatic encephalopathy: serial analysis in plasma and cerebrospinal fluid during treatment with an adapted amino acid solution. Klin. Wochenschr. 1984, 62, 867-875.
45. Schenker, S. & A. M. Hoyumpa Jr: Pathophysiology of hepatic encephalopathy. Hosp. Pract. (Off Ed) 1984, 19, 99-121.
46. Schomerus, H., W. Hamster, H. Blunck, U. Reinhard, K. Mayer & W. Dölle: Latent portasystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive. Dig. Dis. Sci. 1981, 26, 622-630.
47. Schröder, R., O. Müller & J. Bircher: The portacaval and splenocaval shunt in the normal rat. A morphometric and functional reevaluation. J. Hepatol. 1985, 1, 107-123.
48. Sherlock, S., W. H. J. Summerskill, L. P. White & E. A. Phear: Portal-systemic encephalopathy: neurological complications of liver disease. Lancet 1954, 267, 453-457.
49. Sonne, J.: Drug metabolism in liver disease: implications for therapeutic drug monitoring. Ther. Drug Monit. 1996, 18, 397-401.
50. Steindl, P. E., B. Finn, B. Bendok, S. Rothke, P. C. Zee & A. T. Blei: Disruption of the diurnal rhythm of plasma melatonin in cirrhosis. Ann. Intern. Med. 1995a, 123, 274-277.
51. Steindl, P. E., J. Gottstein & A. T. Blei: Disruption of circadian locomotor activity in rats after portacaval anastomosis is not gender-dependent. Hepatology 1995b, 22, 1763-1768.
52. Steindl, P. E., D. L. Coy, B. Finn, P. C. Zee & A. T. Blei: A low-protein diet ameliorates disrupted diurnal locomotor activity in rats after portacaval anastomosis. Amer. J Physiol 1996, 271, G555-G560.
53. Stoeckel, K., J. P. Pfefen, M. Mayersohn, M. P. Schoerlin, C. Andressen, E. E. Ohnhaus, F. Frey & T. W. Guentert: Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function. Acta Psychiatr. Scand. Suppl. 1990, 360, 94-97.
54. Tarter, R. E., A. M. Hegedus & D. H. Van Thiel: Neuropsychiatric sequelae of portal-systemic encephalopathy: a review. Int. J. Neurosci. 1984, 24, 203-216.
55. Tricklebank, M. D., J. L. Smart, D. L. Bloxam & G. Curzon: Effects of chronic experimental liver dysfunction and L-tryptophan on behaviour in the rat. Pharmacol. Biochem. Behav. 1978, 9, 181-189.
56. Turek, F. W.: Circadian neural rhytms in mammals. Ann. Rev. Physiol. 1985, 47, 49-64.
57. Van Cauter, E. & F. W. Turek: Depression: a disorder of time-keeping? Perspect. Biol. Med. 1986, 29, 510-519.
58. von Bahr, C., Ursing, N. Yasui, G. Tybring, L. Bertilsson & S. Röjdmark: Fluvoxamine but not citalopram increases serum melatonin in healthy subjects - an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. Eur. J. Clin. Pharmacol. 2000, 56, 123-127.
59. Zee, P. C., R. Mehta, F. W. Turek & A. T. Blei: (1991) Portacaval anastomosis disrupts circadian locomotor activity and pineal melatonin rhythms in rats. Brain Res. 1991, 560, 17-22.
60. Zheng, Z., M. Jamour & U. Klotz: Stereoselective HPLC-assay for citalopram and its metabolites. Ther. Drug Monit. 2000, 22, 219-224.